AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC
AK112, alone or in combination with chemotherapy for the neoadjuvant/adjuvant treatment of resectable NSCLC
Resectable Non-small Cell Lung Cancer
DRUG: AK112|DRUG: Carboplatin|DRUG: Cisplatin|DRUG: Paclitaxel
Incidence and severity of adverse events (AE), Summary of AE incidence; summary after grading of AE according to NCI CTCAE version 5.0, Up to approximately 2 years|rate of surgical delays, Proportion of subjects exceeding the maximum surgical time window, Up to approximately 2 years|abnormal laboratory findings of clinical significance, Proportion of subjects with abnormal and clinically significant results including routine blood tests, blood biochemical tests, coagulation tests, thyroid function tests, routine urine tests, pregnancy tests, etc., Up to approximately 2 years|MPR, Proportion of subjects with â‰¤10% residual live tumor cells in resected primary tumor foci and lymph nodes, Up to approximately 2 years
R0 resection rate, Proportion of subjects with pathologically complete resection of primary tumors, Up to approximately 2 years|Tumor descending stage rate, Proportion of subjects with the most recent tumor staging prior to surgery (using TNM staging version 8) who were down-staged relative to baseline, Up to approximately 2 years|pCR, Proportion of subjects with no residual tumor in the resected tumor primary and lymph nodes, Up to approximately 2 years|OS, Time from first dose until death from any cause, Up to approximately 2 years|EFS, Time from first dose to the occurrence of any of the following events, whichever occurs first: disease progression, local recurrence or distant metastasis or death from any cause, as assessed according to RECIST v1.1., Up to approximately 2 years|ORR, ORR is the proportion of subjects with CR or PR,based on recist v1.1, Up to approximately 2 years
Phase II clinical study of AK112, an anti-PD-1 and VEGF bispecific antibody, alone or in combination with chemotherapy for the neoadjuvant/adjuvant treatment of resectable non-small cell lung cancer